Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk - Athyros, Vasilios G; Boutari, Chrysa; Stavropoulos, Konstantinos; Anagnostis, Panagiotis; Imprialos, Konstantinos P; Doumas, Michael; Karagiannis, Asterios (Current vascular pharmacology, 2018)
Keywords: Animals; Cardiovascular Diseases - blood; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - epidemiology; Comorbidity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Liver - drug effects; Liver - metabolism; Liver - pathology; Non-alcoholic Fatty Liver Disease - blood; Non-alcoholic Fatty Liver Disease - diagnosis; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - epidemiology; Prevalence; Risk Factors; Treatment Outcome; metabolic syndrome; cardiovascular disease; diabetes mellitus; Non-alcoholic fatty liver disease; statins; non-alcoholic steatohepatitis